TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3886024
Drug: L-tryptophan (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (in women)
Study: 26853287
Drug: L-lysine (3
Normalized name: POLY-L-LYSINE (30000-70000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lysine (3 g/day)
Study: 26853287
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and glibenclamide (standard treatment for both groups)
Study: 25430996
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg testosterone enanthate
Study: 25430996
Drug: 6.25 mg
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.25 mg testosterone enanthate
Study: 25430996
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg testosterone enanthate
Study: 23427401
Drug: Wuziyanzong treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuziyanzong treatment (2.30, 4.60, 9.20 g/kg crude drug) for 30 days
Study: 18279551
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (50 mg/d)
Study: 12848775
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m² with Zosuquidar 3HCl
Study: 12848775
Drug: Paclitaxel 225
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 225 mg/m² with Zosuquidar 3HCl
Study: 12848775
Drug: Paclitaxel alone
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel alone (175 mg/m² or 225 mg/m²)
Study: 27568069
Drug: Integrated PTSD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated PTSD and Smoking Treatment (IPST)
Study: 9657656
Drug: Beta2 agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta2 agonist (salbutamol) inhalation
Study: 7907871
Drug: Bunazosin retard
Normalized name: bunazosin
DrugBank: Bunazosin (DB12230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin retard (6 to 18 mg/day)
Study: 29313415
Drug: Guanfacine extended-release
Normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine extended-release (GXR) plus psychostimulant
Study: 31340800
Drug: Calorie Counting
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calorie Counting (CC)
Study: 16443788
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at rest
Study: 10331397
Drug: Insulin effects
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin effects on glucose uptake and alanine transport
Study: 10331397
Drug: Insulin effects
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin effects on phenylalanine, leucine, and lysine transport
Study: 8942881
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (fortified tobramycin 1.3%-cefazolin 5.0%)
Study: 9810943
Drug: Subcutaneous apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous apomorphine
Study: 7079905
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron plus folic acid
Study: 7079905
Drug: Intravenous iron‐dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron‐dextran (Imferon; Fisons)
Study: 22237735
Drug: Carperitide (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carperitide (0.02 g/kg/min, initiated at the start of surgery and continued for ≥5 days)
Study: 7635541
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous phenylephrine
Study: 3530645
Drug: Intravenous nitroprusside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroprusside
Study: 7635541
Drug: Finapres measurements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finapres measurements during high-dose intravenous phenylephrine
Study: 7635541
Drug: Finapres measurements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finapres measurements during intravenous nitroprusside
Study: 7635541
Drug: Regional infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regional infusion of phenylephrine
Study: 7635541
Drug: Regional infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regional infusion of nitroprusside
Study: 31845837
Drug: Extragonadal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extragonadal steroids
Study: 31845837
Drug: Total androgen
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total androgen receptor transcriptional activity secondary to testosterone, dihydrotestosterone, and androstenedione
Study: 24328444
Drug: Control (hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (hepatitis A vaccine)
Study: 25697247
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline enemas with glycerol (0.8 ml glycerol + 3 ml saline or 1 ml glycerol + 5 ml saline)
Study: 22806274
Drug: Abatacept (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (two different dose regimens)
Study: 20236380
Drug: Q-switched YAG
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-switched YAG laser treatment (Q-YAG 5 system, 1064 nm, Palomar Inc., Burlington, VT, USA); series of three treatments at 6-week intervals.
Study: 20236380
Drug: Punch biopsy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Punch biopsy excision; one treatment.
Study: 12088160
Drug: Nefazodone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (mean final dose = 466 mg/day)
Study: 12088160
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nefazodone (mean dose = 460 mg/day) and CBASP (mean = 16.2 sessions)
Study: 9827437
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of baclofen (initially 156 μg/24 hours, increased to 280 μg/24 hours)
Study: 2559484
Drug: Fragmin (2,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmin (2,500 anti Xa units, subcutaneously, once daily for 5-9 days)
Study: 2559484
Drug: Placebo (subcutaneously,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneously, once daily for 5-9 days)
Study: 206990
Drug: Normal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal treatment program
Study: 31429811
Drug: ondansetron (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (titrated up to 24 mg daily)
Study: 28214385
Drug: HIGH (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH (6 doses of 250 IU/kg over two weeks)
Study: 28214385
Drug: COMB (HIGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMB (HIGH dose plus nine micro-doses over three weeks)
Study: 22136019
Drug: Blood-pricking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-pricking therapy combined with rehabilitation
Study: 22136019
Drug: Blood-pricking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood-pricking therapy
Study: 19592054
Drug: L-arginine (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (6.4 g/d) for 6 months
Study: 17460405
Drug: 0.1% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tacrolimus ointment applied twice daily for 3 weeks
Study: 17460405
Drug: 0.12% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% betamethasone valerate ointment applied twice daily for 3 weeks
Study: 15544076
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue combined with fibrinolysis inhibitor (aprotinin)
Study: 11913478
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg three times daily for 2 months)
Study: 9152114
Drug: Vecuronium bromide
Normalized name: Vecuronium Bromide
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vecuronium bromide (0.15 mg/kg)
Study: 9152114
Drug: Pancuronium bromide
Normalized name: Pancuronium Bromide
DrugBank: Pancuronium (DB01337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pancuronium bromide (0.1 mg/kg)
Study: 9152114
Drug: Saline (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.15 mL/kg)
Study: 7959156
Drug: sulbactam/ampicillin 0.5/1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulbactam/ampicillin 0.5/1.0 g, i.v. administered during surgery and repeated 6 hours later
Study: 26571184
Drug: Albumin and
Normalized name: Bovine serum albumin and glutaraldehyde only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin and crystalloid solutions
Study: 29481425
Drug: Crystalloid solutions
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid solutions alone
Study: 25646891
Drug: 17 of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 of the 20 medications
Study: 20090562
Drug: Enzastaurin plus
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin plus pemetrexed (250 mg two times per day; 500 mg/m intravenously on day 1 of 21-day cycles)
Study: 20090562
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m intravenously on day 1 of 21-day cycles)
Study: 20090562
Drug: Enzastaurin plus
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin plus pemetrexed (combination arm)
Study: 18381986
Drug: Random drug
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random drug testing conducted in school districts
Study: 18381986
Drug: Random drug
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random drug testing for athletes
Study: 18381986
Drug: Random drug
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random drug testing for students in extracurricular activities
Study: 18381986
Drug: Random drug
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random drug testing for all students
Study: 15538040
Drug: Toremifene (TOR)
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toremifene (TOR) 40 mg for 1 year
Study: 15538040
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg for 1 year
Study: 11006188
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (Cetrorelix, 0.25 mg daily) during the late follicular phase
Study: 11006188
Drug: No GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No GnRH agonist or antagonist
Study: 8315554
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg p.o. (oral administration)
Study: 8315554
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg i.m. (intramuscular administration)
Study: 18487998
Drug: Bone marrow-derived
Normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow-derived mononuclear cell therapy
Study: 14686230
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir 1 g three times daily
Study: 31295205
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment program combined with office-based canalith repositioning procedure (CRP)
Study: 31295205
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Home treatment + CRP and CRP only)
Study: 26841526
Drug: Comprehensive spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive spa and health resort-based treatment with manual therapy
Study: 26841526
Drug: Balneotherapeutic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneotherapeutic treatment without manual therapy
Study: 25885729
Drug: 10 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml/kg crystalloid infusion (Group I)
Study: 25885729
Drug: 30 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml/kg crystalloid infusion (Group II)
Study: 17091128
Drug: Naltrexone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (12 mg) + THC (20 mg)
Study: 17091128
Drug: Naltrexone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (12 mg) + THC (40 mg)
Study: 17091128
Drug: Naltrexone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (12 mg) + THC (2.5 mg)
Study: 17091128
Drug: Naltrexone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (12 mg) + THC (10 mg)
Study: 11485281
Drug: Atropa belladonna
Normalized name: ATROPA BELLADONNA
DrugBank: Belladonna (DB13913)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropa belladonna tincture (ABT) 5 ml
Study: 11485281
Drug: Atropa belladonna
Normalized name: ATROPA BELLADONNA
DrugBank: Belladonna (DB13913)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropa belladonna tincture (ABT) 1 ml
Study: 11485281
Drug: Atropa belladonna
Normalized name: ATROPA BELLADONNA
DrugBank: Belladonna (DB13913)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropa belladonna tincture (ABT) 2 ml
Study: 9771953
Drug: Cisplatin at
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin at a dose of 80 mg/m2 on day 1 and etoposide at a dose of 100 mg/m2 on days 1, 2 and 3
Study: 25134034
Drug: Brief alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief alcohol use disorder treatments
Study: 17714844
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg D‐amphetamine alone
Study: 17714844
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg riluzole alone
Study: 15010405
Drug: 3.5% urea-linked
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5% urea-linked gelatin (GEL group)
Study: 8449579
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 125 mg twice daily for three days
Study: 8449579
Drug: Ofloxacin 100
Normalized name: ofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 100 mg twice daily for three days
Study: 31967673
Drug: Bevacizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (8 mg/kg) and Everolimus (4 mg/m2)
Study: 31967673
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg) and Everolimus (4 mg/m2)
Study: 25842470
Drug: Cosmetic topical
Normalized name: Cosmetic Topical application Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cosmetic topical slimming treatment
Study: 23976883
Drug: Sodium dichloroisocyanurate
Normalized name: Sodium dichloroisocyanurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium dichloroisocyanurate (NaDCC) tablets distributed during bi-monthly household visits; intervention included an intensive promotion campaign.
Study: 23976883
Drug: Sodium dichloroisocyanurate
Normalized name: Sodium dichloroisocyanurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium dichloroisocyanurate (NaDCC) tablets intervention.
Study: 19011582
Drug: Continuous passive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous passive motion (CPM) treatment for 1 hour once a day for 20 days over 4 weeks
Study: 19011582
Drug: Conventional physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physiotherapy treatment (CPT) protocol for 1 hour once a day for 20 days over 4 weeks
Study: 11747981
Drug: Metyrapone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (1 g orally daily for 14 days)
Study: 31394939
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field therapy (PEMF) for 12 weeks
Study: 31394939
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field therapy (PEMF) during exercise
Study: 31394939
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field therapy (PEMF) in subjects with resting hypertension (n=11)
Study: 31394939
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field therapy (PEMF) in subjects with resting hypertension
Study: 25308211
Drug: Theracurmin (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theracurmin (180 mg/day)
Study: 20383874
Drug: High-dose NAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose NAC (1200 mg) plus saline hydration (Group 1, n=25)
Study: 18757783
Drug: Odiparcil with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odiparcil with aspirin (ASA)
Study: 11916799
Drug: Bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125% with fentanyl 2 microg/mL at 10 mL/h
Study: 11916799
Drug: Bupivacaine 0.0625%
Normalized name: BUPIVACAINE 0.0625%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.0625% with fentanyl 2 microg/mL at 10 mL/h
Study: 11916799
Drug: Bupivacaine 0.04%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.04% with epinephrine 1:600,000 and fentanyl 2 microg/mL at 10 mL/h
Study: 9583771
Drug: Amantadine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (200 mg)
Study: 8559197
Drug: eberconazole cream
Normalized name: Terconazole
DrugBank: Eberconazole (DB13656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eberconazole cream 1% once daily (group A)
Study: 8559197
Drug: eberconazole cream
Normalized name: Terconazole
DrugBank: Eberconazole (DB13656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eberconazole cream 1% twice daily (group B)
Study: 8559197
Drug: eberconazole cream
Normalized name: Terconazole
DrugBank: Eberconazole (DB13656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eberconazole cream 2% once daily (group C)
Study: 8559197
Drug: eberconazole cream
Normalized name: Terconazole
DrugBank: Eberconazole (DB13656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eberconazole cream 2% twice daily (group D)
Study: 28301292
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PWM red LED light treatment)
Study: 23579103
Drug: Ropivacaine 7.5mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 7.5mg/mL
Study: 21994354
Drug: ACE527 (three-strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE527 (three-strain combination live attenuated vaccine) at doses of 10^10 and 10^11 total CFU
Study: 19523014
Drug: i.v. omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. omeprazole (OME group, 40 mg i.v. infusion every 12 h for 3 days)
Study: 19523014
Drug: oral rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral rabeprazole (RAB group, 20 mg twice daily for 3 days)
Study: 19523014
Drug: oral rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral rabeprazole (RAB group)
Study: 11688083
Drug: Level 1
Normalized name: PALFORZIA (Level 10) KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 1 sugar (10 mg of iron/kg of sugar)
Study: 11688083
Drug: Level 2
Normalized name: True Metrix Control Level 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 2 sugar (100 mg of iron/kg of sugar)
Study: 9716763
Drug: Five weekly
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five weekly practice sessions (Group A)
Study: 2605074
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (control group)
Study: 4394650
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol administration
Study: 4394650
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol administration
Study: 31034700
Drug: Patient-related factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-related factors (gender, socioeconomic status, language spoken at home, lifestyle and comorbidities) and drug-related factors (total number and drug class)
Study: 31034700
Drug: Using cholinergic
Normalized name: PARASYMPATHOMIMETICS (CHOLINERGICS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using cholinergic classes of medications
Study: 25618418
Drug: Wholegrain diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wholegrain diet (>80 g/day)
Study: 25618418
Drug: Refined grain
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined grain diet (<16 g/day)
Study: 22176653
Drug: High-dose ascorbic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ascorbic acid (vitamin C) for 4 weeks
Study: 17071939
Drug: Topotecan 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 0.75 mg/m2, days 1-5, and carboplatin AUC 5, day 5 (arm A)
Study: 17071939
Drug: Topotecan 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.25 mg/m2, days 1-3, and carboplatin AUC 5, day 3 (arm B)
Study: 16291354
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and zinc supplementation (30 mg ferrous fumarate, 30 mg zinc oxide, both, or placebo daily for 6 months)
Study: 6862582
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg) in hyperadrenergic patients
Study: 31082512
Drug: Standardised Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised Chinese herbal medicine (CHM)
Study: 31082512
Drug: Individualised Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised Chinese herbal medicine (CHM)
Study: 24759256
Drug: Grains of
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grains of paradise (GP) extract (30 mg/d) for 4 weeks
Study: 23038982
Drug: Aqueous extract
Normalized name: green tea aqueous extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous extract of dried barberry (600 mg daily for 4 weeks)